登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验,由北京大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07004712,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 1
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(1 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07004712,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
1. Age: 18-75 years old; 2. Small cell lung cancer diagnosed by histology; Compound small cell lung cancer is not allowed; 3. Progress in receiving first-line chemotherapy combined with immunotherapy (including PD-1 inhibitor and PD-L1 inhibitor); 4. According to RECIST 1.1 standard, there is at least one measurable objective lesion; 5.ECOG score 0-1; 6. The functions of important organs meet the following requirements:Bone marrow function: neutrophils ≥1.5×109/L, platelets ≥100×109/L, hemoglobin concentration ≥ 90g/L;Liver function: bilirubin ≤ 1.5× ULN; Aspartate aminotransferase and glutamate aminotransferase ≤2.5×ULN, and AST and ALT ≤ 5× ULN in case of liver metastasis; Total bilirubin ≤1.5 times the upper limit of normal value;Renal function: serum creatinine ≤1.5×ULN, or creatinine clearance rate (CCR) ≥ 60 ml/min; 7. Expected survival > 12 weeks;Patients have good compliance with the planned treatment, can understand the research process of this study and sign a written informed consent.排除标准:Exclusion Criteria:
Irinotecan liposome or Irinotecan has been used before; 2. Severe heart and lung diseases, new york Heart Association (NYHA) scores that patients with heart diseases above Grade II (including Grade II); 3. Patients with severe systemic infection or other serious diseases; 4. Patients who are known to be allergic or intolerant to chemotherapy drugs or their accessories; 5. Other malignant tumors have appeared in the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer; 6. Patients of childbearing age during pregnancy or lactation, and those who refused to take appropriate contraceptive measures during this experiment; 7. Have participated in clinical studies of other drugs within 21 days before the first dose of the study drug is given; 8. Combined with active autoimmune diseases and inflammatory diseases; 9. Grade 3-4 immune-related adverse reactions occurred during previous immunotherapy; 10. Symptomatic brain metastasis and meningeal metastasis; 11. Before the first administration, you are receiving long-term systemic corticosteroid therapy with prednisone > 10mg/d or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy. Subjects who need bronchodilators, inhaled or topical steroids or local steroid injections can be included in this study; 12. Patients with a large amount of serous cavity effusion, or serous cavity effusion with symptoms, or poor control of serous cavity effusion (poor control is defined as: puncture and drainage are needed twice or more in one month);The researcher judges the patients who are not suitable to participate in this study.
引自 ClinicalTrials.gov, NCT07004712, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07004712,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。